Literature DB >> 16564385

Clinicopathologic and immunohistochemical study of intraoral mucoepidermoid carcinoma.

Márcio Ajudarte Lopes1, Danyel Elias da Cruz Perez, Fábio de Abreu Alves, Oslei Paes de Almeida, Luiz Paulo Kowalski.   

Abstract

OBJECTIVE: The purpose of this study is to assess the clinicopathologic and immunohistochemical features of intraoral mucoepidermoid carcinomas and its relationship with the prognosis. STUDY DESIGN AND
SETTING: From 1953 to 1993, 27 patients with intraoral mucoepidermoid carcinomas surgically treated were selected for this study. Clinical data were obtained from the medical records, the microscopic slides were reviewed, the tumors were graded, and immunohistochemical analysis for p53, PCNA, cerbB-2, and CEA were carried out.
RESULTS: The tumors were more frequent in patients between 40 and 60 years of age (40.7%), without gender predilection. Hard palate was the most common site with 13 cases (48%). T2 was the more frequent stage (48%) and 2 patients (7.4%) were staged as N+. Most tumors (48%) were classified as low grade of malignancy. The expression of PCNA was associated to high-grade tumors (P = .00610) and c-erbB-2 to low grade tumors (P = .03958). No recurrence was noted in most of the cases (22 cases, 81.5%). Three cases (11.1%), however, showed local recurrence and 2 patients (7.4%) died because of the disease. The analysis of the overall survival rate showed that male patients (P = .04249), stage N (P = .05948), high grade of malignancy (P = .0009), strong expression of PCNA (P = .09128), and weak expression of c-erbB-2 (P = .03334) had the lowest survival rates.
CONCLUSION: Our results showed that patients with intraoral mucoepidermoid carcinoma had a reduced survival expectation if they were of the male gender, with regional metastasis, high grade of malignancy, strong expression of PCNA and weak expression of c-erbB-2. EBM RATING: C-4.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16564385     DOI: 10.1016/j.otohns.2005.12.012

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  The Role of Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Mucoepidermoid Carcinomas.

Authors:  Shirin Saravani
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells.

Authors:  Luan César Silva; Gabriell Bonifácio Borgato; Vivian Petersen Wagner; Manoela Domingues Martins; Guilherme Zweig Rocha; Márcio Ajudarte Lopes; Alan Roger Santos-Silva; Gilberto de Castro Júnior; Luiz Paulo Kowalski; Jacques E Nor; Cristiane H Squarize; Rogerio Moraes Castilho; Pablo Agustin Vargas
Journal:  J Oral Pathol Med       Date:  2021-10-27       Impact factor: 3.539

3.  Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma.

Authors:  Melonie A Nance; Raja R Seethala; Yun Wang; Simion I Chiosea; Eugene N Myers; Jonas T Johnson; Stephen Y Lai
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

4.  Prognostic factors of palatal mucoepidermoid carcinoma: a retrospective analysis based on a double-center study.

Authors:  Wenguang Xu; Yufeng Wang; Xiaofeng Qi; Junqi Xie; Zheng Wei; Xiteng Yin; Zhiyong Wang; Jian Meng; Wei Han
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

Review 5.  Advances in the Treatment of Mucoepidermoid Carcinoma.

Authors:  Srikar Sama; Takefumi Komiya; Achuta Kumar Guddati
Journal:  World J Oncol       Date:  2021-12-08

6.  Postoperative radiotherapy for thymus salivary gland carcinoma: A case report.

Authors:  Rui Deng; Nan-Jing Li; Liang-Liang Bai; Shi-Hong Nie; Xiao-Wen Sun; Yong-Sheng Wang
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.